Bayer revises its 2026 profit forecasts upwards following excellent results from its pharmaceutical division - Business AM
Article excerpt
Highlighted: the sentence this signal was extracted from
Following a better-than-expected third quarter in its pharmaceutical division, German group Bayer has revised its 2026 profit forecasts upwards. The company now expects its core profit, adjusted for exchange rate effects, to total between 9.8 and 10.3 billion euros for the full year. This represents an increase from previous forecasts, which ranged between 9.6 and 10.1 billion euros. The pharmaceutical division posted strong results, with quarterly revenue of 4.68 billion euros. This figure is 5 percent higher than analysts' forecasts. The company's adjusted EBITDA for the third quarter also exceeded market expectations, coming in at 1.62 billion euros, or about 13 percent higher than anticipated. CEO Bill Anderson stated that the pharmaceutical division is entering a new phase of growth. Financially, the group is working to pay down the massive debt incurred during the 56.2 billion euro acquisition of Monsanto in 2018, a deal that also resulted in costly legal disputes regarding the Roundup herbicide. Bayer has revised its year-end net debt forecast downward by 1 billion euros, now expecting it to be around 29 billion euros. Regarding the legal disputes, Bill Anderson stated that a 6.47 billion euro settlement aimed at resolving Roundup-related lawsuits is expected to be finalized before the end of the year, though this agreement still requires court approval. This...
Keep reading with a free account
The rest of this article, and every signal for Bayer, is in your free account.
